Sickle cell disease patient HSPCs that have been treated with a vector containing both a ZNF410 and a BCL11A shRNAmiRs and differentiated into erythrocytes led to an increase of 10% HbF and a significant decrease of sickled cells in comparison to BCL11A shRNAmiR only vector treated cells [70]. The gene discussed is BCL11A; the disease is sickle cell disease.